Recently, Novatim Immune Therapeutics (Zhejiang) Co., Ltd. announced that the "Meeting for the Initiation of Phase I Clinical Trial Project to Evaluate the Safety, Tolerance, Preliminary Efficacy and Pharmacokinetic Characteristics of KQ-2003 CAR-T Cell Injection in Patients with POEMS Syndrome" was successfully held at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences. This marks the official launch of the Phase I clinical trial of KQ-2003 CAR-T Cell Injection for POEMS Syndrome.
The meeting was chaired by Professor Jian Li, the director of the Hematology Department of Beijing Peking Union Medical College Hospital and a doctoral supervisor. As the main researcher (leading PI) of the leading unit, he delivered an opening speech for this kick-off meeting, stating: "I am very honored to serve as the main PI for the Phase I clinical trial of KQ-2003 for POEMS syndrome. KQ-2003 has demonstrated excellent efficacy and safety data in both the IIT clinical research and the Phase I formal clinical trial for patients with relapsed/refractory multiple myeloma. I look forward to KQ-2003 bringing better therapeutic effects and hope to patients with POEMS syndrome, and I wish the Phase I clinical trial project of KQ-2003 for POEMS syndrome to be completed on schedule as planned."
Regarding the operation, execution plan and trial protocol of the Phase I clinical trial of KQ-2003 POEMS syndrome, Professor Lu Zhang, the deputy director of the Hematology Department of Peking Union Medical College Hospital, gave a detailed introduction. The experts present conducted a thorough and in-depth discussion and analysis of the trial protocol, laying a solid foundation for the scientific and standardized implementation of the Phase I clinical research.
About KQ-2003
KQ-2003 is a next-generation dual-target CAR-T cell therapy developed based on Novatim’s enhanced CAR-T platform. Through parallel structural design and optimized signaling domains, KQ-2003 significantly improves CAR-T cell persistence and anti-tumor activity while reducing relapse risks seen in traditional CAR-T therapies. Its core advantages include: outstanding efficacy, superior safety profile, and cost competitiveness. It has achieved promising efficacy and superior safety profile in Phase I trials for relapsed/refractory multiple myeloma (rrMM) and POEMS syndrome.
About Novatim
Founded in 2018, Novatim is a biotechnology company dedicated to the development and clinical application of innovative immuno-oncology therapeutics. Based on unmet clinical needs and differentiated innovation, Novatim has built three core R&D platforms: Bispecific Antibody Platform，Nanobody-based ADC Platform，Enhanced Dual-target CAR-T Platform.
The company has independently developed more than ten novel and differentiated FIC/BIC pipelines from scratch. Based on the bispecific antibody platform, Novatim developed China's first βγ-biased PD-1/IL-2 fusion protein, now in Phase Ib trials in China with IND clearance in both China and the U.S.; Based on the nanobody-ADC platform, Novatim developed the world's first nanobody-based bispecific ADC, currently in Phase Ia in China and IND-cleared in the U.S.; Based on its dual-target CAR-T platform, Novatim developed the world's first enhanced parallel dual-target CAR-T, now in Phase I/IIa clinical trials.
